MedTrace Logo

Piclidenoson for Treatment of COVID-19

NCT04333472 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-04-22

No results posted yet for this study

Summary

Patients with documented moderate COVID-19 infection will be randomized 1:1 to receive piclidenoson 2 mg Q12H orally with standard supportive care (SSC - intervention arm) or placebo orally with SSC (control arm) for up to 28 days.

Conditions

Interventions

DRUG

Piclidenoson

Piclidenoson 2 mg orally every 12 hours for up to 28 days

DRUG

Placebo

Placebo orally every 12 hours for up to 28 days

Sponsors & Collaborators

  • Rabin Medical Center

    collaborator OTHER

  • Can-Fite BioPharma

    lead INDUSTRY

Principal Investigators

  • Zivit Harpaz · Can-Fite BioPharma Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-06
Primary Completion
2022-03-06
Completion
2022-04-21
FDA Drug
Yes

Countries

  • Bulgaria
  • Israel
  • Romania

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04333472 on ClinicalTrials.gov